
Aurinia Pharmaceuticals Inc: updates and filings
Price
$14.92
November 19, 2026Market cap $2.0B
What Ploutos Investor adds for Aurinia Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 30, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 30, 2026Results of operationsForm8-K
- Aug 26, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 19, 2026Other material eventsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 4, 2026Shareholder voteForm8-K
- May 11, 2026Acquisition or disposal of assetsForm8-K
- May 11, 2026Filing (amendment)FormSC TO-T/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Apr 13, 2026FilingFormSC TO-T
- Apr 3, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Mar 25, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 23, 2026Officer or director changeForm8-K
- Mar 3, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Nov 4, 2025Results of operationsForm8-K
- Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Aug 13, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 31, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Jul 31, 2025Results of operations, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 30, 2026 | 8-K | Results of operations | Document |
| Aug 26, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 19, 2026 | 8-K | Other material events | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 11, 2026 | 8-K | Acquisition or disposal of assets | Document |
| May 11, 2026 | SC TO-T/A | Filing (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 13, 2026 | SC TO-T | Filing | Document |
| Apr 3, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Mar 25, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 23, 2026 | 8-K | Officer or director change | Document |
| Mar 3, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2025 | 8-K | Results of operations | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Aug 13, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 31, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Jul 31, 2025 | 8-K | Results of operations, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 28, 2014.
The full analysis
What do Aurinia Pharmaceuticals's filings show?
The filings are where every one of Aurinia Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.